Ipsen Biopharmaceuticals, Inc. Announces FDA Approval of Dysport(R) (Abobotulinumtoxin A) for the Treatment of Lower Limb Spasticity in Pediatric Patients Aged Two and Older
BASKING RIDGE, N.J., Aug. 1, 2016 -- (Healthcare Sales & Marketing Network) -- Ipsen Biopharmaceuticals, Inc., a subsidiary of Ipsen SA (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that the U.S. Food and Drug Administration (FDA) has approved its ... Biopharmaceuticals, FDA Ipsen Biopharmaceuticals, Dysport, abobotulinumtoxin A, botulinum toxin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 1, 2016 Category: Pharmaceuticals Source Type: news
Ipsen Announces FDA Approval of Dysport(R) (abobotulinumtoxinA) for Injection for the Treatment of Lower Limb Spasticity in Children Aged Two and Older
PARIS--(Healthcare Sales & Marketing Network)--Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical group, today announced that the U.S. Food and Drug Administration (FDA) has approved Dysport® (abobotulinumtoxinA) for injection ... Biopharmaceuticals, FDA Ipsen, Dysport, abobotulinumtoxinA, lower limb spasticity (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 1, 2016 Category: Pharmaceuticals Source Type: news
Botox-Like Injection Might Ease Runners' Knee Pain
British researchers used Dysport to bring long-term relief for common ailment of physically active people (Source: WebMD Health)
Source: WebMD Health - February 22, 2016 Category: Consumer Health News Source Type: news
Botox-Like Injection Might Ease Runners' Knee Pain
British researchers used Dysport to bring long-term relief for common ailment of physically active people (Source: U.S. News - Health)
Source: U.S. News - Health - February 22, 2016 Category: Consumer Health News Source Type: news
Lavenburg Medical Group Announces Transition From Botox to Dysport for Skin Tightening and Anti-Wrinkle Treatments
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - October 4, 2015 Category: Pharmaceuticals Source Type: news
FDA accepts to review Ipsen's sBLA for Dysport to treat upper limb spasticity in adults
The US Food and Drug Administration (FDA) has accepted for review French pharmaceutical firm Ipsen's supplemental Biologics License Application (sBLA) for Dysport (abobotulinumtoxinA) to treat upper limb spasticity in adult patients. (Source: Drug Development Technology)
Source: Drug Development Technology - December 1, 2014 Category: Pharmaceuticals Source Type: news
Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe1
Ipsen and Galderma to expand their current distribution agreement for Dysport®/Azzalure® in aesthetic and dermatology indications to the US and Canada
Ipsen and Galderma to collaborate on development and commercialization of new neurotoxins, inc... Biopharmaceuticals, Dermatology, DistributionIpsen, Galderma, Dysport, Azzalure (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 11, 2014 Category: Pharmaceuticals Source Type: news
Ipsen Says Dysport Incontinence Treatment Trial PositiveIpsen Says Dysport Incontinence Treatment Trial Positive
French drugmaker Ipsen said it had seen positive results from the first stage of a phase II trial of its Dysport brand in treating patients with a certain type of urinary incontinence. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 19, 2014 Category: Consumer Health News Tags: Urology News Source Type: news
France's Ipsen says Dysport incontinence treatment trial positive
PARIS (Reuters) - French drugmaker Ipsen said it had seen positive results from the first stage of a phase II trial of its Dysport brand in treating patients with a certain type of urinary incontinence. (Source: Reuters: Health)
Source: Reuters: Health - March 18, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
Ipsen Reorganizes Its US Neurology Platform and Confirms Its Goal to Become Profitable in the US in 2014
PARIS--(Healthcare Sales & Marketing Network)--Ipsen (Euronext: IPN; ADR: IPSEY) (IPN.PA) today announced that, as part of the accelerated execution of its strategy in the USA, the Group adopted a new organizational model for the distribution of Dysport&re... Biopharmaceuticals, NeurologyIpsen, Dysport (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 14, 2013 Category: Pharmaceuticals Source Type: news
